Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other financing activities (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Other financing activities for 3 consecutive years, with $983000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities changed N/A to $983000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $983000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $10.4 million for FY2025, N/A changed from the prior year.
  • Other financing activities for Q4 2025 was $983000.0 at Madrigal Pharmaceuticals, up from $75000.0 in the prior quarter.
  • The five-year high for Other financing activities was $983000.0 in Q4 2025, with the low at $75000.0 in Q2 2023.
  • Average Other financing activities over 3 years is $446400.0, with a median of $213000.0 recorded in 2023.
  • Peak annual rise in Other financing activities hit 91.53% in 2023, while the deepest fall reached 91.53% in 2023.
  • Over 3 years, Other financing activities stood at $886000.0 in 2022, then crashed by 91.53% to $75000.0 in 2023, then skyrocketed by 1210.67% to $983000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $983000.0, $75000.0, and $75000.0 for Q4 2025, Q3 2023, and Q2 2023 respectively.